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25-hydroxyvitamin D (25(OH)D) plays a crucial role in human homeostasis. Its deficiency (vitamin D deficiency—VDD), being
common in European population, combined with elevated concentration of parathyroid hormone (PTH), represents a vicious
cycle of mechanisms leading to heart failure (HF). Despite several papers published in that field, the effect of VDD and PTH
concentration on cardiovascular system remains unequivocal; thus, the aim of the study was to compare these data among HF
and non-HF patients being prospectively enrolled into the study during hospital stay in the cardiology ward. Patients with HF
had higher PTH concentration (85.0± 52.6 versus 64.5± 31.7, p = 0 02) compared to non-HF patients. Mean PTH values were
associated with the clinical status expressed by the New York Heart Association class (NYHA class) (“0”—66.04, “I”—56.57,
“II”—72.30, “III”—85.59, and “IV”—144.37 pg/ml, p = 0 00004). Interestingly, neither 25(OH)D (31.5 versus 29.7 ng/ml, p = ns)
nor phosphorus (P) (1.23 versus 1.18mmol/l, p = ns) nor total calcium (Ca2+) concentration (2.33 versus 2.37mmol/l, p = ns)
differed among the groups. Reassuming PTH serum concentration in contrary to 25(OH)D, P and Ca2+ are significantly raised
among the patients with HF and shows significant relationship with the clinical status expressed by the NYHA class.
1. Introduction
A lipid-soluble vitamin D has huge impact on human
homeostasis [1]. It is produced during sun exposure and
delivered via nutrients (including oily fish and egg yolks),
as well as dietary supplements [2]. Vegetable sources pro-
vide ergocalciferol (D2), and animal sources provide chole-
calciferol (D3). Ergocalciferol and cholecalciferol represent
similar metabolic flux being transported to the liver by a
vitamin D-binding protein (DBP) and then submitted for
hydroxylation at the C25 position by specific hydroxylase.
25-hydroxyvitamin D is the main circulating form of vita-
min D [3]. Low serum 25-hydroxyvitamin D (25(OH)D)
concentrations are a predominant cause of a negative cal-
cium balance and secondary hyperparathyroidism (SHPT).
SHPT is a frequently occurring entity in patients suffer-
ing from heart failure (HF). Since parathormone (PTH) is
an important regulator of bone and mineral metabolism, its
biological activity is regulated by oscillations in serum
calcium concentrations with subsequent reactions on several
pathways. The main purpose of those mechanisms is to raise
serum concentration of calcium due to enhancement of renal
and intestinal reabsorption and osteoclast activation leading
to bone resorption. PTH rise in HF clinical setting is related
to the impairment of acid-based homeostasis, diuretic-
induced calcium loss, and vitamin D deficiency (VDD).
Moreover, increased PTH concentrations are related to the
impaired hemodynamic state expressed by reduced stroke
volume and increased pulmonary capillary wedge pressure
being commonly observed in HF patients during right heart
catheterization [4].
It is worth to emphasize that 1,25-dihydroxyvitamin D
and 25-hydroxyvitamin D have, beyond their important role
in calcium and phosphorus metabolism, diverse effects on
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the immune system [5]. Vitamin D has been reported to pro-
tect tissue from myocardial and cerebral ischemia [6, 7].
Many evidence suggests a critical role of vitamin D in
blood pressure (BP) regulation; 25(OH)D deficiency stim-
ulates renin-angiotensin-aldosterone system (RAAS) and
promotes hypertension [8]. Worldwide studies have shown
an association between VDD and tissue inflammation,
endothelial dysfunction, arterial stiffness, atherosclerotic
plaque formation (coronary heart disease [CAD], periph-
eral arterial disease), left ventricular hypertrophy, atrial
fibrillation, metabolic syndrome, and diabetes. VDD is also
associated with an increased risk of death, heart failure,
and myocardial infarction (MI) in postmenopausal
women, as well as with an increased risk of stroke, MI,
and sudden cardiac death or/and death related to other
heart diseases among diabetic patients with chronic kidney
disease (CKD) [9–18].
VDD is common in European population due to indoor
lifestyle and sun avoidance. In Central Europe (CE) effective
vitamin D synthesis occurs from April to October only if at
least twenty percent of skin is exposed to sunlight for the
minimal time of fifteen minutes daily. Sunscreens limit the
synthesis in 90%; additionally, VDD is frequently related
to smoking, obesity, renal and liver failure, inappropriate
eating habits, and drug intake. VDD in obese patients
may result from low outdoor activity, inappropriate eating
habits, and sequestration of fat-soluble cholecalciferol in
adipose tissue [1, 19–22].
VDD combined with raised PTH represents a vicious
cycle of mechanisms on one hand leading to HF and in the
other hand worsening the prognosis of HF. It is worth to
mention that myocardial fibrosis and hypertrophy, excessive
adrenergic stimulation, calcium cell overload, oxidative stress
enhancement, and FGF-23 formation have huge impact on
impaired survival [23].
2. Aim of the Study
The aim of the study is to assess and compare the serum
intact PTH and 25(OH)D in HF and non-HF patients being
prospectively enrolled into the study during hospital stay in
the cardiology ward.
3. Material and Methods
3.1. General Information. This cross-sectional study was
designed to asses serum intact PTH, 25(OH)D, total calcium
(Ca2+), and phosphorus (P) concentrations in addition to
routine laboratory examinations and medical history
obtained on admission in 140 consecutive patients hospital-
ized in a clinical ward of cardiology form November 15 to
December 31, 2014. The study complies with the Declaration
of Helsinki and was approved by the local ethics committee
(number of approval KNW/0022/KB1/40/I/12/13), and all
patients gave informed consent prior to enrollment.
3.2. Inclusion and Exclusion Criteria. Inclusion criteria were
as follows: impaired systolic function with left ventricular
ejection fraction (LVEF) below 50% according to the
Simpson method in the echocardiographic examination or
patient diagnosed and/or treated due to HF prior to admis-
sion, CAD diagnosed on the base of invasive/noninvasive
testing performed before admission, or if patient was previ-
ously submitted for coronary intervention. Exclusion criteria
were as follows: lack of consent, under eighteen years of age,
vitamin D supplementation, or CKD stage four or higher.
Invasive coronary angiography (CAG) was found positive
for CAD if at least one coronary artery of at least two
millimeters was significantly stenosed.
3.3. Group Formation. Finally, 127 patients were enrolled
into the study. Demographic and clinical data were recorded
on admission to the hospital. Patients were requested to
characterize their daily profile of sun exposure during the
last four months as “above” or “below” seven hours a
week (one hour per day).
Patients were post hoc divided into four groups depend-
ing on CAD and/or HF occurrence. HF patients were divided
into two groups according to the etiology of HF. Ischemic is
defined as impaired systolic function with significant nar-
rowings in coronary tree (IHF) and nonischemic (N-IHF)
is defined as impaired systolic function without significant
narrowings in coronary tree.
Patients with CAD but without HF were depicted as
(CAD N-HF) and formed the third group. Patients not
fulfilling inclusion criteria of CAD nor HF were depicted
as (N-HF&N-CAD) and referred to the fourth group.
3.4. Diagnostic Techniques and Further Definitions. Serum
concentrations of intact PTH and 25(OH)D were assessed
using the immunoenzymatic assay technique with theMicro-
Vue Intact PTH ELISA and 25(OH)-Vitamin D Xpress
ELISA Kit, respectively. Serum P and Ca2+ concentration
was assessed using the enzymatic method as described by
Spinreact S.A., Spain, and the colorimetric Arsenazo III
method as described by Biomaxima S.A., Poland.
Arterial hypertension was diagnosed if systolic and
diastolic blood pressures exceeded 140 and/or 90mmHg or
if the patient already received antihypertensive treatment.
Diabetes was diagnosed according to the American Diabetes
Association (ADA) criteria or in patients already receiving
antidiabetic medication. The estimated glomerular filtration
CAD
(n−37)
No CAD
(n−13)
CAD
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HF
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Figure 1: Subgroups of patients. HF: heart failure; No HF: heart
failure absent; CAD: coronary artery disease present; No CAD:
coronary artery disease absent.
2 Disease Markers
rate (eGFR) was calculated on the basis of the Modification of
Diet in Renal Disease (MDRD) formula.
For the design of the study and patient characteristic,
please refer to Figure 1 and Table 1.
4. Statistical Analysis
Distributions of the examined parameters were analyzed
using the Shapiro-Wilk test. Values were presented as the
mean and standard deviation (SD) or as the median in the
25th and 75th percentiles. Nominal and categorical values
were expressed in percentages or proportional rates. Linear
variables with normal distribution were compared using
student t-test. Post hoc analyses between the groups were
performed by the use of factorial ANOVA test with the
Bonferroni correction. Variables with abnormal distribution
were compared using the Mann–Whitney U test. Categorical
variables of abnormal distribution were compared using
Table 1: Patient characteristic divided depending on heart failure occurrence.
HF present (n – 50) HF absent (n – 77) p
Age 61.5 (57.0–74.0) 65.3 (57.0–74.0) ns
Male (%) 36 (72) 43 (56) ns
BMI 28.1 (24.3–30.9) 28.5 (25.4–31.2) ns
Hypertension 38 (76) 61 (79) ns
Dyslipidemia 32 (64) 38 (49) ns
Diabetes 15 (30) 27 (35) ns
Atrial fibrillation 14 (28) 8 (10) 0.02
Urgent admission 22 (44) 34 (44) ns
Sun exposure>7 h/week 26 (52) 50 (65) ns
Coronary artery disease 39 (78) 59 (77) ns
EDV (ml) 146.2± 55.9 86.3± 20.9 0.001
LVEF (%) 28.7± 11.7 55.9± 4.7 0.001
ICD 12 (24) 1 (1) 0.001
CRT 2 (4) 0 (0) ns
DDDR 2 (4) 13 (17) 0.06
VVIR 2 (4) 5 (5) ns
OHT 2 (4) 0 (0) ns
DEATH (during hospitalization) 2 (4) 2 (3) ns
HF: heart failure; BMI: body mass index; >7 h/week: more than seven hours per week; EDV: end-diastolic volume; LVEF: left ventricular ejection fraction; ICD:
implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; DDDR: dual chamber permanent pacemaker; VVIR: single chamber
permanent pacemaker; OHT: orthotopic heart transplantation.
Table 2: Clinical and laboratory findings depending on heart
failure occurrence.
HF present
(n – 50)
HF absent
(n – 77) p
eGFR (ml/min/1.732) 76.1± 26.1 82.9± 22.6 0.09
Creatinine (mmol/l) 90.0± 30.9 81.1± 48.5 0.01
ALT (IU/l) 30.5± 21.4 31.2± 22.6 ns
AST (IU/l) 35.5± 34.2 27.1± 14.3 ns
HGB (g/dl) 13.5± 1.5 13.6± 1.5 ns
HCT (%) 41.3± 6.9 41.8± 6.0 ns
RBC (106/ul) 4.47± 0.6 4.46± 0.5 ns
PLT (103/ul) 203.8± 66.6 210.0± 53.8 ns
WBC (103/ul) 7.5± 2.6 6.8± 2.2 ns
25(OH)D (ng/ml) 31.5± 8.94 29.7± 10.2 ns
Ca2+ (mmol/l) 2.33± 0.13 2.37± 0.1 ns
P (mmol/l) 1.23± 0.17 1.18± 0.2 ns
PTH (pg/ml) 85.0± 52.6 64.5± 31.7 0.02
HF: heart failure; eGFR: estimated glomerular filtration rate; ALT: alanine
aminotransferase; AST: aspartate aminotransferase; HGB: hemoglobin;
HCT: hematocrit; RBC: red blood cells; PLT: platelets; WBC: white blood
cells; 25(OH)D: 25-hydroxyvitamin D; Ca2+: total calcium; P: phosphorus;
PTH: parathyroid hormone.
PTH-T3
PTH-T2
PTH-T1
24 (48%) versus 19 (25%); p = 0.01
12 (24%) versus 30 (39%); p = 0.12
14 (28%) versus 28 (36%); p = 0.43
HF-0
HF-1
Figure 2: Incidence of HF divided according to tertiles of PTH
serum concentration. HF: heart failure; PTH: parathyroid
hormone; T: tertile.
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Table 3: Laboratory findings among all examined groups.
HF CAD No CAD
N-IHF
n – 13
IHF
n – 37
IHF
n – 37
CAD N-HF
n – 59
N-IHF
n – 13
N-HF & N-CAD
n – 18
Parameter Versus p Versus p Versus p
25(OH)D (ng/ml) 29.25 32.29 ns 32.29 29.47 ns 29.25 31.00 ns
Ca2+ (mmol/l) 2.36 2.32 ns 2.32 2.37 ns 2.36 2.37 ns
P (mmol/l) 1.21 1.23 ns 1.23 1.18 ns 1.21 1.18 ns
PTH (pg/ml) 85.26 84.91 ns 84.91 64.24 0.06 85.26 62.67 ns
eGFR (ml/min/1.732) 67.38 79.14 ns 79.14 81.15 ns 67.38 87.88 ns
Creatinine (mmol/l) 96.00 87.89 ns 87.89 84.11 ns 96.00 71.06 ns
ALT (IU/l) 35.23 28.84 ns 28.84 29.73 ns 35.23 37.47 ns
AST (IU/l) 38.69 34.41 ns 34.41 26.32 ns 38.69 30.53 ns
HGB (g/dl) 13.52 13.48 ns 13.48 13.51 ns 13.52 13.80 ns
HCT (%) 42.44 40.86 ns 40.86 41.36 ns 42.44 42.97 ns
RBC (106/ul) 4.61 4.42 ns 4.42 4.43 ns 4.61 4.53 ns
PLT (103/ul) 169.62 215.78 0.04 215.78 212.29 ns 169.62 202.88 ns
WBC (103/ul) 6.68 7.79 ns 7.79 7.04 0.04 6.68 5.87 ns
N-IHF: nonischemic heart failure; IHF: ischemic heart failure; CAD N-HF: coronary artery disease without heart failure; N-HF&N-CAD: without coronary
artery disease nor heart failure; 25(OH)D: 25-hydroxyvitamin D; Ca2+: total calcium; P: phosphorus; PTH: parathyroid hormone; eGFR: estimated
glomerular filtration rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase; HGB: hemoglobin; HCT: hematocrit; RBC: red blood cells;
PLT: platelets; WBC: white blood cells.
Table 4: Clinical findings among all examined groups.
HF CAD No CAD
n (%)
N-IHF
n – 13
IHF
n – 37
IHF
n – 37
CAD N-HF
n – 59
N-IHF
n – 13
N-HF & N-CAD
n – 18
Parameter Versus p Versus p Versus p
Age (years) 51.54 65.00 0.001 65.00 66.37 ns 51.54 62.82 0.03
BMI 25.83 28.91 ns 28.91 28.43 ns 25.83 29.02 ns
EDV (ml) 163.08 140.32 ns 140.32 87.03 0.001 163.08 84.82 0.001
LVEF (%) 24.62 30.11 ns 30.11 55.25 0.001 24.62 58.53 0.001
Male 8 (62) 28 (76) ns 28 (76) 34 (58) ns 8 (62) 8 (47) ns
HT 5 (38) 33 (89) 0.001 33 (89) 49 (83) ns 5 (38) 12 (71) ns
DYSLIP 4 (31) 28 (76) 0.01 28 (76) 31 (53) 0.04 4 (31) 7 (41) ns
Diabetes 3 (23) 12 (32) ns 12 (32) 24 (41) ns 3 (23) 3 (18) ns
AF 4 (31) 10 (28) ns 10 (28) 5 (8) 0.03 4 (31) 3 (18) ns
Urgent 4 (31) 18 (49) ns 18 (49) 28 (47) ns 4 (31) 6 (35) ns
SE> 7 h/w 7 (54) 19 (51) ns 19 (51) 41 (69) ns 7 (54) 9 (53) ns
ICD 5 (38) 7 (19) ns 7 (19) 0 (0) 0.001 5 (38) 1 (6) ns
CRT 1 (8) 1 (3) ns 1 (3) 0 (0) ns 1 (8) 0 (0) ns
DDDR 0 (0) 2 (5) ns 2 (5) 8 (14) ns 0 (0) 5 (29) ns
VVIR 1 (8) 1 (3) ns 1 (3) 2 (3) ns 1 (8) 2 (12) ns
OHT 2 (15) 0 (0) ns 0 (0) 0 (0) ns 2 (15) 0 (0) ns
Death 0 (0) 2 (5) ns 2 (5) 2 (3) ns 0 (0) 0 (0) ns
N-IHF: nonischemic heart failure; IHF: ischemic heart failure; CAD N-HF: coronary artery disease without heart failure; N-HF&N-CAD: without coronary
artery disease nor heart failure; BMI: body mass index; EDV: end-diastolic volume; LVEF: left ventricular ejection fraction; HT: hypertension; DYSLIP:
dyslipidemia; AF: atrial fibrillation; urgent: urgent admission; SE > 7 h/week: sun exposure exceeding seven hours per week; ICD: implantable cardioverter-
defibrillator; CRT: cardiac resynchronization therapy; DDDR: dual chamber permanent pacemaker; VVIR: single chamber permanent pacemaker;
OHT: orthotopic heart transplantation.
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Chi-squared test with Yates correction. Quantified Spear-
man’s rho correlation coefficients were used to assess the
linear correlations between LVEF and PTH among all speci-
fied groups. Differences between the values were considered
statistically significant if P < 0 05. Analyses were performed
using Statistica 10 with medical package (Statsoft Inc.).
5. Results
Patients with HF had higher incidence of atrial fibrillation
(AF) and were characterized by significant negative remodel-
ing of the left ventricle expressed by lower LVEF and higher
end-diastolic volume (EDV). Incidence of implantable
cardioverter-defibrillator (ICD) was significantly elevated in
the HF group and reached borderline significance as far as
frequency of dual chamber permanent pacemaker (DDDR)
was concerned. The remaining parameters depicted in
Table 1 did not show statistically significant differences.
Patients with HF had deteriorated renal function
expressed by significantly increased serum creatinine
concentration and dropped eGFR of borderline statistical
significance. PTH in HF patients was significantly elevated.
There was no incidence of PTH-dependent hypercalcemia in
examined group of patients. The rest of the findings are
depicted in Table 2 and did not show statistical significance.
The number of patients with the PTH serum concentra-
tion values in the third tertile was significantly raised among
HF versus non-HF patients—data are presented in Figure 2.
Patients in N-IHF group were younger, had lower
occurrence rate of hypertension and dyslipidemia, and had
significantly decreased platelet blood count compared to
IHF group of patients. Patients in CAD N-HF group had
decreased white blood count and EDV and increased LVEF
compared to IHF group of patients with trend towards signif-
icance considering PTH serum blood concentration. Data are
depicted in Tables 3 and 4.
N-IHF patients were younger, had significantly decreased
LVEF, and had increased EDV compared with N-HF&N-
CAD group of patients. Dyslipidemia, AF, and ICD
implantation in IHF patients were observed more frequently
compared to CAD N-HF group of patients. The remaining
parameters did not show statistical significance among the
groups—data were presented in Tables 3 and 4.
The mean PTH concentration was significantly increased
in patients in worse clinical state expressed by the NYHA
class; results were reported in Figure 3 and in Table 5.
PTH and LVEF showed statistically significant correla-
tion in all patients, in HF and in IHF patients. In N-IHF
patients, only borderline significance was reported. There
was no significant correlation in patients without HF. Data
were presented in Table 6.
PTH concentration showed statistically significant corre-
lation with EDV, LVEF, serum creatinine concentration,
eGFR, and N-terminal probrain natriuretic peptide serum
concentration (NT-proBNP). Data were presented in Table 7.
PTH concentration was significantly elevated in patients
treated with loop diuretics (LD), with the highest values
observed in HF patients. Data was presented in Table 8.
Neither PTH nor 25(OH)D concentrations were depen-
dent on self-reported sun exposure in HF and N-HF patients.
6. Discussion
The presented study, according to our best knowledge, is the
first to compare vitamin D, PTH, calcium, and phosphorus
serum concentration in cardiology ward patients with and
without HF taking into account its etiology (ischemic versus
nonischemic). There were no differences in vitamin D con-
centration among the groups although it oscillated between
lower normal limits.
Self-reported sunlight exposure is a novel approach. The
cut-off value was set up on one hour per day what we believe
provides optimal vitamin D synthesis.
Patients with HF had higher rates of PTH, irrespectively
of its etiology what remains in line with previously published
studies [23–27]. PTH concentration in HF correlates with
disease severity, expressed by decreased LVEF, increased
EDV, and functional NYHA class. It also correlates with
lower eGFR and higher NT-proBNP concentration what is
coherent with previous reports [28–31].
SHPT, being an exclusive cause of elevated PTH concen-
tration in our study, is a common state in HF patients origi-
nating from several overlapping mechanisms. Increased
aldosterone activity (compensatory activation of RAAS)
and loop diuretic intake promote excessive urine calcium
and magnesium loss. Renal dysfunction, due to chronic
hypoperfusion, increases P retention and 25(OH)D activa-
tion disturbance (decreased activity of renal 1-alpha-
hydroxylase induced by uremia), which stimulates PTH
secretion. This is coherent with our findings: LD intake
affected PTH concentration in all participants; its predomi-
nant influence was observed in HF patients.
25(OH)D insufficiency, common in HF, is also a cause of
SHPT [29, 30]. There are reports showing independent
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Figure 3: Mean plot of PTH grouped by NYHA class. NYHA: New
York Heart Association; PTH: parathyroid hormone.
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association between higher PTH level and an exacerbated
risk of HF in the general population [28]. SHPT increases
bone turnover and the risk of fractures; it is also associated
with cardiovascular calcifications and higher mortality risk.
Treatment of severe SHPT in CKD is based on control of
dietary phosphate intake, gastrointestinal absorption (chelat-
ing agents), vitamin D supplementation, and calcimimetic
drug intake [32]. It is not fully elucidated whether treatment
of SHPT in HF patients has beneficial effect on prognosis;
thus, we think further studies are required in this field.
Polish Society of Endocrinology recommends at least
15 minutes of sun exposure of 15–20% of body surface
daily, from April to October, in order to provide optimal
25(OH)D serum concentration [33]. In our analysis, the
assumed criterion of optimal-declared sun exposure time
was above 7 hours per week during the last 4 months, which
was equivalent of one hour per day and outstrips common
recommendations. The study was performed during Novem-
ber and December; thus, 25(OH)D concentration to a lesser
degree depended on endogenous 25(OH)D synthesis.
There were no differences between examined groups in
self-reported sunlight exposure; it also had no influence on
vitamin D or PTH concentration. Against the odds, HF
patients did not declare decreased sun exposure in compari-
son to the rest of the cardiology ward patients. Moreover,
self-reported sunlight exposition did not affect 25(OH)D
serum concentration: in group of higher sun exposure,
25(OH)D serum concentration was 30.73 ng/ml versus
29.89 ng/ml (p = ns). Partially, it could have resulted from the
lack of skin synthesis in months preceding blood sampling,
from a relatively small number of study participants or from
patients’ personal fitness overrating and disease negation.
Decreased serum 25(OH)D concentration in HF patients,
correlating with disease severity, was reported by numerous
authors [34]. In our research, mean 25(OH)D concentration
did not differ among the groups which corroborates with our
previous findings [31].
CE population, with regard to latitude, is prone to
25(OH)D deficiency especially during winter. Despite the
fact that blood samples were collected in November and
December, mean 25(OH)D concentration oscillated between
normal limits in both groups. 25(OH)D deficiency requiring
treatment (<20ng/ml) occurred in 30 patients (23.6%), and
suboptimal concentration (20–30ng/ml) was stated in 24
participants (18.9%). The range of 25(OH)D concentration
was 12.0–46.6 ng/ml in all patients. Recent large cross-
sectional study reported by Płudowski et al. showed consider-
able prevalence of 25(OH)D deficiency in Polish volunteers,
with mean concentration amounting 18.0± 9.6 ng/ml; defi-
ciency (<20 ng/ml) occurred in 65.8% participants, and
Table 5: PTH values (pg/ml) divided according to NYHA class.
NYHA N Mean Median Lower quartile Upper quartile SD p
All 127 72.54 60.93 42.61 88.80 42.26 0.00004∗∗
0 73 66.04 57.49 42.61 82.24 31.29 0.000001∗
I 7 56.57 47.11 25.00 65.81 41.06 0.000043∗
II 33 72.30 72.01 48.55 89.97 34.15 0.000017∗
III 7 85.59 89.86 38.44 112.93 49.19 0.005274∗
IV 7 144.37 117.97 62.70 203.98 91.66 —
∗∗All effects tested by ANOVA; ∗Post hoc comparison versus NYHA IV by the use of Fischer LSD test. NYHA: New York Heart Association;
SD: standard deviation.
Table 7: Correlation between PTH and subsequent parameters.
All patients Spearman Rho coefficients p
EDV 0.269 0.002205
LVEF −0.290 0.000953
eGFR −0.375 0.000014
creatinine 0.407 0.000002
NT-proBNP 0.449 0.016441
EDV: end diastolic volume; LVEF: left ventricle ejection fraction; eGFR:
estimated glomerular filtration rate; NT-proBNP: N-terminal probrain
natriuretic peptide.
Table 6: Correlation between PTH concentration and LVEF in
different groups of patients.
Group of patients Spearman Rho coefficients p
All (n – 127) −0.3479 0.00006
HF (n – 50) −0.4168 0.0026
N-HF (n – 77) 0.0480 ns
N-IHF (n – 13) −0.5409 0.0563
IHF (5) −0.3883 0.0176
HF: heart failure; N-HF: without heart failure; N-IHF: nonischemic heart
failure; IHF: ischemic heart failure.
Table 8: PTH concentration (pg/ml, mean± SD) according to loop
diuretic intake and HF occurrence.
Loop diuretic intake (+) (−) p
All (n = 127) (n = 46)
99.09± 53.78
(n = 81)
58.26± 26.89 0.00000015
HF (n = 50) (n = 28)
105.77± 58.45
(n = 22)
60.15± 30.49 0.000452
N-HF (n = 77) (n = 14)
84.06± 39.48
(n = 63)
57.63± 25.87 0.008666
HF patients: heart failure patients; N-HF patients: patients without heart
failure. Loop diuretics: furosemide and torasemide.
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suboptimal concentration (20–30 ng/ml) was stated in 24.1%.
Sampling was performed in March and May and mean
25(OH)D concentration in late winter was 17.7± 10.1 ng/ml,
in spring 18.3 0± 9.1 ng/ml, respectively [35]. Discrepancies
between these values were most probably caused by different
time of blood sampling, considering the half-life of 25(OH)D
defined was twenty-five days, and lack of skin synthesis in
winter could influence the findings. This so-called “seasonal
effect” being coherent with our results was also reported by
Tokarz et al. in the acute myocardial infarction group of
patients [36]. It is worth tomention that 25(OH)D concentra-
tionduringwinter is basedupon food intake andprevious liver
storage. Comparing to Płudowski et al. [35], our patients were
older (63.8 versus 54.0 years), had higher BMI (28.3 versus
26.0), and were mostly men (62.2% versus 22.7%). Moreover,
measurements were performed with laboratory assays pro-
vided by different companies. The problem of 25(OH)D stan-
dardization had been brought up in previously published
studies. Immunoassays, being sensitive to 24,25-dihydroxyvi-
tamin D, can overrate the serum 25(OH)D concentrations up
to 5ng/ml [37–40].
On the other hand, Gruson et al. showed that
1,25(OH)2D, but not 25(OH)D, correlates with NYHA
functional class in chronic heart failure patients, especially
that 1,25(OH)2D to PTH(1–84) ratio is a promising predic-
tor of cardiovascular death in HF [41, 42]. There are some
other reports showing that 25(OH)D deficiency was not
related to HF in contrast to PTH [43, 44]. Being aware of lim-
itations, we decided to asses 25(OH)D in our study because
of easier access and lower costs than 1,25(OH)D assessment,
as well as the wide range of other studies comparing
25(OH)D concentration in circulatory system.
Patients with AF had higher PTH concentration. In
HF group, AF occurrence was more frequent, what is
related to adverse remodeling of the myocardium but also
may be affected by elevated PTH concentration, which is a
proarrhythmic agent. An opposite causal link is also pre-
sumable: AF may promote PTH elevation [45]. In CAD
group, higher number of white blood cells was observed
when compared to patients without ischemia, with the
highest values in IHF. It could be explained by the most
excessive inflammatory state in advanced atherosclerosis,
complicated by heart muscle damage. Statistically, signifi-
cant difference between PLT count in IHF versus N-IHF
(215.78 versus 169.62, p = 0 04) group of patients is related
with unfavorable prognosis and was widely reported in the
literature [46–48].
7. Limitations of the Study
The results of the study might have been biased on several
pathways. The main limitation of this study is its cross-
sectional design, self-reported data about sun exposure,
and relatively small amount of patients; however, the study
had a strictly pilot character. The researchers did not
interfere with the management process; nevertheless, the
data were acquired from a single cardiology center provid-
ing management to the population of approximately one
million inhabitants.
8. Conclusions
PTH serum concentration is significantly raised in patients
with HF irrespectively of its etiology and correlates with
LVEF, NYHA functional class, renal function, and loop
diuretics intake. Vitamin D serum concentration oscillates
between lower normal limit in all patients and is not
affected by the HF, CAD occurrence, or declared exposure
to sun radiation.
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